Maxalt Rapitab

Rizatriptan, the active ingredient in Maxalt Rapitab, is a selective 5‑HT1B/1D receptor agonist classified as a triptan and presented as an orally disintegrating tablet for oral administration. It is indicated for the acute treatment of migraine attacks, with or without aura, in adult patients.

GNH USA supplies Maxalt Rapitab as a licensed, Good Distribution Practice‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide. Our supply chain ensures product integrity and timely delivery to meet clinical demand.

Maxalt Rapitab (rizatriptan) is used in the acute migraine treatment pathway to alleviate headache episodes.

Migraine with aura: provides rapid relief of headache and associated symptoms. Migraine without aura: reduces pain intensity and duration. Acute migraine attacks: enables patients to treat an episode once it begins.

Rizatriptan may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Taste disturbance: a temporary metallic or bitter taste that usually resolves without treatment. - Dry mouth: reduced saliva production causing throat dryness and difficulty swallowing. - Dizziness: sensation of light‑headedness or unsteady balance that may last a few hours. - Nausea: mild stomach upset that often improves as the migraine resolves.

Serious or Rare Side Effects: - Chest discomfort or pain: may signal coronary vasospasm and requires immediate medical evaluation. - Serotonin syndrome: rare but severe condition with agitation, high fever, muscle rigidity, especially when combined with other serotonergic drugs. - Severe allergic reaction: includes rash, swelling of face or throat, and breathing difficulty, needing urgent care.

When prescribing or dispensing Maxalt Rapitab, consider the following precautions.

Cardiovascular assessment: avoid in patients with uncontrolled hypertension or coronary artery disease. Medication history: review use of other serotonergic agents to prevent serotonin syndrome. Age considerations: safety not established in adolescents; use only as prescribed for adults. Pregnancy and lactation: risk unknown; prescribe only if benefits outweigh potential risks. Driving and machinery: may cause dizziness; caution advised. Store at ambient temperature below 25°C: keep in original packaging, protect from moisture.

Rizatriptan may interact with other medicines; assess patient medication profile.

Major Interactions (Avoid): - MAO inhibitors: concurrent use can precipitate severe hypertension. - Other triptans or ergot derivatives: combined vasoconstrictive effect may increase cardiovascular risk. - SSRIs, SNRIs, or other serotonergic drugs: risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase rizatriptan plasma levels. - CYP3A4 inducers (e.g., rifampin): may reduce efficacy of rizatriptan.